These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 5005690)

  • 21. Extrastriatal dopamine and Parkinson's disease.
    Parent A; Cossette M
    Adv Neurol; 2001; 86():45-54. PubMed ID: 11554008
    [No Abstract]   [Full Text] [Related]  

  • 22. The structural and biochemical basis of movement disorders in treatment with neuroleptic drugs and in extrapyramidal diseases.
    Faurbye A
    Compr Psychiatry; 1970 May; 11(3):205-25. PubMed ID: 4315299
    [No Abstract]   [Full Text] [Related]  

  • 23. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative mechanisms in nigral cell death in Parkinson's disease.
    Jenner P
    Mov Disord; 1998; 13 Suppl 1():24-34. PubMed ID: 9613715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's syndrome--modern therapy, known facts and unanswered questions.
    Albert E
    Pharmakopsychiatr Neuropsychopharmakol; 1973 Sep; 6(5):229-46. PubMed ID: 4604872
    [No Abstract]   [Full Text] [Related]  

  • 26. [Parkinson's syndrome. 5. Pathophysiologic mechanisms].
    Steg G
    Lakartidningen; 1970 Oct; 67(42):4821-3. PubMed ID: 5478707
    [No Abstract]   [Full Text] [Related]  

  • 27. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 28. Dopamine, extrapyramidal system, and psychomotor function.
    Papeschi R
    Psychiatr Neurol Neurochir; 1972; 75(1):13-48. PubMed ID: 4625495
    [No Abstract]   [Full Text] [Related]  

  • 29. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.
    Paillé V; Henry V; Lescaudron L; Brachet P; Damier P
    Mov Disord; 2007 Mar; 22(4):533-9. PubMed ID: 17230470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fundamental investigation of neural transplantation for Parkinson's disease in mice.
    Shimizu K; Matsui Y; Tamura K; Tsuda N; Yamamoto K; Okamoto Y; Yamada M; Hayakawa T; Mogami H
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3171-3. PubMed ID: 2705276
    [No Abstract]   [Full Text] [Related]  

  • 31. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tremor of attitude: physiopathologic study].
    Hardy J; Molina-Negro P; Bertrand C; Martinez NS
    Union Med Can; 1970 Mar; 99(3):449-56. PubMed ID: 5435623
    [No Abstract]   [Full Text] [Related]  

  • 34. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extrapyramidal rigidity. An electromyographic and pathophysioloical study of the tonic stretch and shortening reflexes.
    Polák O
    Acta Univ Carol Med (Praha); 1970; ():Suppl 42:1+. PubMed ID: 4251096
    [No Abstract]   [Full Text] [Related]  

  • 37. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
    Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
    Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
    Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
    J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presymptomatic detection of Parkinson's disease.
    Jenner P
    J Neural Transm Suppl; 1993; 40():23-36. PubMed ID: 8294898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tremor in Parkinson's disease patients can be induced by uncontrolled activation and uninhibited synchronization of alpha2-motoneuron firing to which alpha1-motoneuron firing synchronizes.
    Schalow G
    Electromyogr Clin Neurophysiol; 2005 Dec; 45(7-8):393-406. PubMed ID: 16438347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.